Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 8;11:419. doi: 10.3389/fphar.2020.00419

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Zimmer, Shea, Tobin, Tchernychev, Germano, Sykes, Banijamali, Jacobson, Bernier, Sarno, Carvalho, Chien, Graul, Buys, Jones, Wakefield, Price, Chickering, Milne, Currie and Masferrer

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of olinciguat on blood pressure, cardiac weights, lung weights, and NT-proBNP in Dahl salt-sensitive rat. (A) Mean arterial pressure vs time profiles in NS and HS controls, and HS rats treated with olinciguat 10 mg/kg (OLI10). HS groups were put on the HS diet starting Week-2. Olinciguat treatment was started on Week 0. Data are plotted as daily average MAP + SEM. (B) Weight of left ventricular wall plus ventricular septum normalized to BW. (C) Lung weight normalized to BW. (D) Plasma NT-proBNP. Data in (B–D) are plotted as mean + SEM, **p < 0.01, ***p < 0.001 vs HS control. For the OLI10 group, MAP measurements that were significantly (p < 0.05) lower than vehicle-treated rats are indicated by filled rectangles.